Turn Biotechnologies, Inc. announced that it has received an oversubscribed round of funding on April 12, 2022. The transaction included participation from Astellas Venture Management LLC, Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd and other venture capital firms.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
37,600 KRW | +1.76% | +12.07% | -15.12% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.12% | 1.38B | |
+37.87% | 705B | |
+32.82% | 583B | |
-3.66% | 364B | |
+20.21% | 332B | |
+4.95% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.73% | 169B |
- Stock Market
- Equities
- A009420 Stock
- News Hanall Biopharma Co., Ltd.
- Turn Biotechnologies, Inc. announced that it has received funding from Astellas Venture Management LLC, Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd and other investors